Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Cash from Investing Activities (2016 - 2019)

Historic Cash from Investing Activities for Outlook Therapeutics (OTLK) over the last 5 years, with Q3 2019 value amounting to -$1.0.

  • Outlook Therapeutics' Cash from Investing Activities rose 9999.99% to -$1.0 in Q3 2019 from the same period last year, while for Sep 2019 it was -$437307.0, marking a year-over-year increase of 8427.59%. This contributed to the annual value of -$900000.0 for FY2020, which is 10580.51% down from last year.
  • According to the latest figures from Q3 2019, Outlook Therapeutics' Cash from Investing Activities is -$1.0, which was up 9999.99% from -$150737.0 recorded in Q2 2019.
  • Outlook Therapeutics' 5-year Cash from Investing Activities high stood at $46949.0 for Q1 2016, and its period low was -$3.5 million during Q2 2015.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$202226.5 (2018), whereas its average is -$632910.3.
  • In the last 5 years, Outlook Therapeutics' Cash from Investing Activities tumbled by 516595.5% in 2018 and then soared by 9999.99% in 2019.
  • Over the past 5 years, Outlook Therapeutics' Cash from Investing Activities (Quarter) stood at -$364242.0 in 2015, then skyrocketed by 59.27% to -$148362.0 in 2016, then tumbled by 624.68% to -$1.1 million in 2017, then soared by 78.01% to -$236433.0 in 2018, then skyrocketed by 100.0% to -$1.0 in 2019.
  • Its Cash from Investing Activities stands at -$1.0 for Q3 2019, versus -$150737.0 for Q2 2019 and -$50136.0 for Q1 2019.